Literature DB >> 16350272

Thalidomide therapy and deep venous thrombosis in multiple myeloma.

S Vincent Rajkumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16350272     DOI： 10.4065/80.12.1549

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  12 in total

Review 1.  Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.

Authors:  Nicole M Kuderer; Gary H Lyman
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

2.  Treatment of newly diagnosed multiple myeloma.

Authors:  Antonio Palumbo; Valeria Magarotto; Alessandra Larocca; Sara Bringhen; Patrizia Falco; Francesco Di Raimondo; Luca Baldini; Mario Boccadoro
Journal:  Curr Hematol Malig Rep       Date:  2008-04       Impact factor: 3.952

3.  Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.

Authors:  Rajshekhar Chakraborty; Irbaz Bin Riaz; Saad Ullah Malik; Naimisha Marneni; Alex Mejia Garcia; Faiz Anwer; Alok A Khorana; S Vincent Rajkumar; Shaji Kumar; M Hassan Murad; Zhen Wang; Safi U Khan; Navneet S Majhail
Journal:  Cancer       Date:  2020-01-08       Impact factor: 6.860

4.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

5.  Thromboembolic events with lenalidomide-based therapy for multiple myeloma.

Authors:  Smitha Patiyil Menon; S Vincent Rajkumar; Martha Lacy; Patrizia Falco; Antonio Palumbo
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

Review 6.  Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

Authors:  Rohit Moudgil; Edward T H Yeh
Journal:  Can J Cardiol       Date:  2016-02-02       Impact factor: 5.223

7.  Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.

Authors:  Xionghu Yang; Nancy A Brandenburg; John Freeman; Maria Luisa Salomon; Jerome B Zeldis; Robert D Knight; Robert Bwire
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

8.  Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Authors:  David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

Review 9.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927

Review 10.  New therapies in multiple myeloma.

Authors:  F Merchionne; F Perosa; F Dammacco
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.